• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of the advanced practitioner in oncology >Prostate Cancer: ASCO2O Virtual Scientific Program Highlights for the Advanced Practitioner
【24h】

Prostate Cancer: ASCO2O Virtual Scientific Program Highlights for the Advanced Practitioner

机译：前列腺癌：ASCO2O虚拟科学节目为先进的科学家突出显示

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Initial results of the randomized phase II TheraP trial show that therapy directed to prostate-specific membrane antigen (PSMA) with lutetium-177-labeled PSMA-617 (LuPSMA) significantly improved prostate-specific antigen (PSA) response compared with cabazitaxel in men with metastatic castration-resistant prostate cancer that had progressed on docetaxel. LuPSMA had an improved toxicity profile as well. "This is the first randomized trial to compare LuPSMA with a standard of care in men with docetaxel-progressing metastatic castration-resistant prostate cancer," stated lead author Michael S. Hofman, FRACP, MBBS, of Peter MacCallum Cancer Centre, Melbourne. "Cabazitaxel, the comparator, is a relevant comparator that has been shown to improve overall survival in men who have disease progression on docetaxel," he added.
机译：随机II期TheraP试验的初步结果表明，在多西他赛治疗的转移性去势耐受前列腺癌患者中，与卡巴齐他塞尔相比，使用镥-177标记的PSMA-617（LuPSMA）针对前列腺特异性膜抗原（PSMA）的治疗显著改善了前列腺特异性抗原（PSA）的反应。羽扇豆的毒性也有所改善。“这是首个将LuPSMA与多西紫杉醇进展性去势抗转移性前列腺癌患者的标准护理进行比较的随机试验，”墨尔本彼得·麦克卡勒姆癌症中心的首席作者迈克尔·S·霍夫曼（Michael S.Hofman，FRACP，MBBS）说。他补充说：“卡巴齐他塞尔是一种相关的比较药物，已被证明能提高多西他赛治疗的进展期男性患者的总体生存率。”。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号